Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Turning on the Left Side Electrode Changed Depressive State to Manic State in a Parkinson's Disease Patient Who Received Bilateral Subthalamic Nucleus Deep Brain Stimulation: A Case Report.

Kinoshita M, Nakataki M, Morigaki R, Sumitani S, Goto S, Kaji R, Ohmori T.

Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):494-496. doi: 10.9758/cpn.2018.16.4.494.

2.

Phenotype variability and allelic heterogeneity in KMT2B-Associated disease.

Kawarai T, Miyamoto R, Nakagawa E, Koichihara R, Sakamoto T, Mure H, Morigaki R, Koizumi H, Oki R, Montecchiani C, Caltagirone C, Orlacchio A, Hattori A, Mashimo H, Izumi Y, Mezaki T, Kumada S, Taniguchi M, Yokochi F, Saitoh S, Goto S, Kaji R.

Parkinsonism Relat Disord. 2018 Jul;52:55-61. doi: 10.1016/j.parkreldis.2018.03.022. Epub 2018 Apr 5.

PMID:
29653907
3.

Clinicopathological Phenotype and Genetics of X-Linked Dystonia-Parkinsonism (XDP; DYT3; Lubag).

Kawarai T, Morigaki R, Kaji R, Goto S.

Brain Sci. 2017 Jun 26;7(7). pii: E72. doi: 10.3390/brainsci7070072. Review.

4.

Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.

Morigaki R, Goto S.

Brain Sci. 2017 Jun 7;7(6). pii: E63. doi: 10.3390/brainsci7060063. Review.

5.
6.

Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.

Morigaki R, Mure H, Kaji R, Nagahiro S, Goto S.

Front Psychiatry. 2016 Dec 26;7:207. doi: 10.3389/fpsyt.2016.00207. eCollection 2016. Review.

7.

Putaminal Mosaic Visualized by Tyrosine Hydroxylase Immunohistochemistry in the Human Neostriatum.

Morigaki R, Goto S.

Front Neuroanat. 2016 Apr 5;10:34. doi: 10.3389/fnana.2016.00034. eCollection 2016.

8.

Postsynaptic Density Protein 95 in the Striosome and Matrix Compartments of the Human Neostriatum.

Morigaki R, Goto S.

Front Neuroanat. 2015 Nov 30;9:154. doi: 10.3389/fnana.2015.00154. eCollection 2015.

9.

Autopsy case of severe generalized dystonia and static ataxia with marked cerebellar atrophy.

Miyamoto R, Sumikura H, Takeuchi T, Sanada M, Fujita K, Kawarai T, Mure H, Morigaki R, Goto S, Murayama S, Izumi Y, Kaji R.

Neurology. 2015 Oct 27;85(17):1522-4. doi: 10.1212/WNL.0000000000002061. Epub 2015 Sep 25. No abstract available.

PMID:
26408497
10.

Development of a highly sensitive immunohistochemical method to detect neurochemical molecules in formalin-fixed and paraffin-embedded tissues from autopsied human brains.

Goto S, Morigaki R, Okita S, Nagahiro S, Kaji R.

Front Neuroanat. 2015 Mar 3;9:22. doi: 10.3389/fnana.2015.00022. eCollection 2015.

11.

Deep brain stimulation of the thalamic ventral lateral anterior nucleus for DYT6 dystonia.

Mure H, Morigaki R, Koizumi H, Okita S, Kawarai T, Miyamoto R, Kaji R, Nagahiro S, Goto S.

Stereotact Funct Neurosurg. 2014;92(6):393-6. doi: 10.1159/000365577. Epub 2014 Oct 28.

PMID:
25359437
12.

Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.

Koizumi H, Goto S, Okita S, Morigaki R, Akaike N, Torii Y, Harakawa T, Ginnaga A, Kaji R.

Front Neurol. 2014 Jun 23;5:98. doi: 10.3389/fneur.2014.00098. eCollection 2014.

13.

Reversibility of ischemic findings on 3-tesla magnetic resonance T2(*)-weighted image after recanalization.

Yamamoto N, Terasawa Y, Satomi J, Morigaki R, Fujita K, Harada M, Izumi Y, Nagahiro S, Kaji R.

J Med Invest. 2014;61(1-2):190-6.

14.

A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease.

Tanabe A, Yamamura Y, Kasahara J, Morigaki R, Kaji R, Goto S.

Front Cell Neurosci. 2014 Feb 20;8:50. doi: 10.3389/fncel.2014.00050. eCollection 2014.

15.

[Pathomechanisms of motor neuron death by mutant TFG].

Kawarai T, Morita M, Morigaki R, Fujita K, Nodera H, Izumi Y, Goto S, Nakano I, Kaji R.

Rinsho Shinkeigaku. 2013;23(11):1199. Japanese.

PMID:
24291928
16.

Brush sign on 3-T T2*-weighted MRI as a potential predictor of hemorrhagic transformation after tissue plasminogen activator therapy.

Terasawa Y, Yamamoto N, Morigaki R, Fujita K, Izumi Y, Satomi J, Harada M, Nagahiro S, Kaji R.

Stroke. 2014 Jan;45(1):274-6. doi: 10.1161/STROKEAHA.113.002640. Epub 2013 Oct 30.

PMID:
24172577
17.

Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role.

Koizumi H, Morigaki R, Okita S, Nagahiro S, Kaji R, Nakagawa M, Goto S.

Front Cell Neurosci. 2013 May 17;7:74. doi: 10.3389/fncel.2013.00074. eCollection 2013.

18.

Depression in X-linked dystonia-parkinsonism: a case-control study.

Morigaki R, Nakataki M, Kawarai T, Lee LV, Teleg RA, Tabuena MD, Mure H, Sako W, Pasco PM, Nagahiro S, Iga J, Ohmori T, Goto S, Kaji R.

Parkinsonism Relat Disord. 2013 Sep;19(9):844-6. doi: 10.1016/j.parkreldis.2013.04.027. Epub 2013 May 23. No abstract available.

PMID:
23706616
19.

Defects in the striatal neuropeptide Y system in X-linked dystonia-parkinsonism.

Goto S, Kawarai T, Morigaki R, Okita S, Koizumi H, Nagahiro S, Munoz EL, Lee LV, Kaji R.

Brain. 2013 May;136(Pt 5):1555-67. doi: 10.1093/brain/awt084. Epub 2013 Apr 18.

PMID:
23599389
20.

Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice.

Yamamura Y, Morigaki R, Kasahara J, Yokoyama H, Tanabe A, Okita S, Koizumi H, Nagahiro S, Kaji R, Goto S.

Front Cell Neurosci. 2013 Feb 14;7:12. doi: 10.3389/fncel.2013.00012. eCollection 2013.

Supplemental Content

Loading ...
Support Center